Chiroscience signs deal for asthma drug

Chiroscience shares jumped 17.5p to 255p yesterday after the biotechnology group announced a tie-up with Schering-Plough of the US in a deal worth up to $38m (pounds 23m) to develop asthma and other drugs.

The US group, regarded as number three in the treatment of respiratory diseases, will underwrite the research and development of Chiroscience's class of anti-inflammatory treatments known as PDE IV inhibitors, including what is being claimed as the leading treatment for asthma, codenamed D4418. In exchange, Schering will be given exclusive world-wide rights to any drugs which result from the research.

John Padfield, Chiroscience chief executive, said asthma was a growing problem, affecting some 14 per cent of the Western World's population. "To be working on our PDE IV inhibitors with a company of the calibre of Schering-Plough is exciting and acknowledges the success we have achieved to date with D4418 and other research compounds," he said.

Chiroscience estimates the Western market for asthma drugs is worth around $4bn, but claims that only half of all sufferers are treated due to difficulties in using treatments. Children, for instance, have problems using inhalers to take drugs such as Glaxo's Becotide, one of the leading treatments for asthma. Chiroscience's product will be in pill form. However, it is not expected to reach the market before 2003, even if it clears clinical trials currently under way in phase I.

Last year, Celltech, another biotech group, and Merck of the US abandoned development of a rival PDE IV-based product, codenamed CDP840. Chiroscience now reckons it has the lead in this class of drug, which it claims is the only one which attacks all four main components of asthma - wheezing at the beginning and after an attack and the associated inflammation and phlegm brought up from the stomach.

Other uses for the treatment being researched include chronic bronchitis, rheumatoid arthritis and the skin conditions atopic eczema and psoriasis.

The group will receive an initial licence fee, milestone payments and research and development finance under the Schering deal, with any royalty payments coming in on top of the initial $38m maximum.

Separately, Shire Pharmaceuticals, another biotech group, announced it had secured certain exclusive marketing rights to distribute Urispas, a urinary treatment, from Recordati of Italy.

Start your day with The Independent, sign up for daily news emails
News
ebooksAn unforgettable anthology of contemporary reportage
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Recruitment Genius: Digital Optimisation Executive - Marketing

£30000 - £35000 per annum: Recruitment Genius: The UK's fastest growing, multi...

Recruitment Genius: Financial Reporting Manager

£70000 - £90000 per annum: Recruitment Genius: A Financial Reporting Manager i...

Recruitment Genius: Payments Operations Assistant

£23000 - £25000 per annum: Recruitment Genius: They win lots of awards for the...

Recruitment Genius: Telephone Debt Negotiator

£13500 - £20000 per annum: Recruitment Genius: This nationwide enforcement com...

Day In a Page

Sepp Blatter resignation: The beginning of Fifa's long road to reform?

Does Blatter's departure mean Fifa will automatically clean up its act?

Don't bet on it, says Tom Peck
Charles Kennedy: The baby of the House who grew into a Lib Dem giant

The baby of the House who grew into a Lib Dem giant

Charles Kennedy was consistently a man of the centre-left, dedicated to social justice, but was also a champion of liberty and an opponent of the nanny-state, says Baroness Williams
Syria civil war: The harrowing testament of a five-year-old victim of this endless conflict

The harrowing testament of a five-year-old victim of Syria's endless civil war

Sahar Qanbar lost her mother and brother as civilians and government soldiers fought side by side after being surrounded by brutal Islamist fighters. Robert Fisk visited her
The future of songwriting: How streaming is changing everything we know about making music

The future of songwriting

How streaming is changing everything we know about making music
William Shemin and Henry Johnson: Jewish and black soldiers receive World War I Medal of Honor amid claims of discrimination

Recognition at last

Jewish and black soldiers who fought in WWI finally receive medals after claims of discrimination
Beating obesity: The new pacemaker which helps over-eaters

Beating obesity

The new pacemaker which helps over-eaters
9 best women's festival waterproofs

Ready for rain: 9 best women's festival waterproofs

These are the macs to keep your denim dry and your hair frizz-free(ish)
Cycling World Hour Record: Nervous Sir Bradley Wiggins ready for pain as he prepares to go distance

Wiggins worried

Nervous Sir Bradley ready for pain as he prepares to attempt cycling's World Hour Record
On your feet! Spending at least two hours a day standing reduces the risk of heart attacks, cancer and diabetes, according to new research

On your feet!

Spending half the day standing 'reduces risk of heart attacks and cancer'
Liverpool close in on Milner signing

Liverpool close in on Milner signing

Reds baulk at Christian Benteke £32.5m release clause
With scores of surgeries closing, what hope is there for the David Cameron's promise of 5,000 more GPs and a 24/7 NHS?

The big NHS question

Why are there so few new GPs when so many want to study medicine?
Big knickers are back: Thongs ain't what they used to be

Thongs ain't what they used to be

Big knickers are back
Thurston Moore interview

Thurston Moore interview

On living in London, Sonic Youth and musical memoirs
In full bloom

In full bloom

Floral print womenswear
From leading man to Elephant Man, Bradley Cooper is terrific

From leading man to Elephant Man

Bradley Cooper is terrific